Vysera Biomedical is engaged in the development of therapies that can be delivered directly to target sites on the inner surface of the gastrointestinal (GI) tract via conventional minimally invasive techniques. Diseases of the inner surface or ‘lumen’ of the GI tract affect a significant number of people worldwide and have historically been treated using prolonged pharmaceutical regimens or in some critical cases invasive procedures have been used. The deployment of directly targeted endoluminal therapies within an outpatient environment represents a potentially remarkable improvement to the patient’s quality of life.